Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581553 · ClinicalTrials.gov registry record · Phase 1
Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability
A Phase 1 study of Healthy, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT02581553: Completed Phase 1 study of Healthy, sponsored by Ardea Biosciences.
NCT02581553 is a Phase 1 study of Healthy that has completed, run by Ardea Biosciences. The registered enrollment target is 116 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02581553, a Phase 1 study of Healthy, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess relative bioavailability of lesinurad/allopurinol fixed dose combination (FDC), its individual components and the effect of food.
Primary Outcome
Cmax is the maximum observed concentration of a drug after administration
Conditions Studied
Interventions
- DRUG lesinurad/allopurinol 200/300 FDC tablets
- DRUG lesinurad 200 mg
- DRUG allopurinol 300 mg
- DRUG lesinurad/allopurinol 200/200 FDC tablets
- DRUG allopurinol 200 mg
Study Locations (1)
Texas
- - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
What the finished NCT02581553 record still lists
NCT02581553 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which lesinurad/allopurinol 200/300 FDC tablets is the first listed.
NCT02581553 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02581553 about?
NCT02581553 is a clinical study titled "Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability". This study will assess relative bioavailability of lesinurad/allopurinol fixed dose combination (FDC), its individual components and the effect of food.
What is the current status of trial NCT02581553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2015-10. Estimated completion is 2016-08.
What conditions does trial NCT02581553 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02581553?
The interventions under investigation include: lesinurad/allopurinol 200/300 FDC tablets (DRUG), lesinurad 200 mg (DRUG), allopurinol 300 mg (DRUG), lesinurad/allopurinol 200/200 FDC tablets (DRUG), allopurinol 200 mg (DRUG).
Who is sponsoring clinical trial NCT02581553?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02581553 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02581553's enrollment target sits among peer trials
116 198th of 1090 higher than 892 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia